Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 185


Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.

Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ.

Immunity. 2007 Jul;27(1):111-22. Epub 2007 Jul 12.


Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.

Ito T, Ueno T, Clarkson MR, Yuan X, Jurewicz MM, Yagita H, Azuma M, Sharpe AH, Auchincloss H Jr, Sayegh MH, Najafian N.

J Immunol. 2005 Jun 1;174(11):6648-56.


The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.

Paterson AM, Brown KE, Keir ME, Vanguri VK, Riella LV, Chandraker A, Sayegh MH, Blazar BR, Freeman GJ, Sharpe AH.

J Immunol. 2011 Aug 1;187(3):1097-105. doi: 10.4049/jimmunol.1003496. Epub 2011 Jun 22.


Tissue expression of PD-L1 mediates peripheral T cell tolerance.

Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH, Sharpe AH.

J Exp Med. 2006 Apr 17;203(4):883-95. Epub 2006 Apr 10.


Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice.

Gotsman I, Grabie N, Dacosta R, Sukhova G, Sharpe A, Lichtman AH.

J Clin Invest. 2007 Oct;117(10):2974-82.


The B7 family of ligands and its receptors: new pathways for costimulation and inhibition of immune responses.

Carreno BM, Collins M.

Annu Rev Immunol. 2002;20:29-53. Epub 2001 Oct 4. Review.


Programmed death-1 (PD-1):PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes.

Keir ME, Latchman YE, Freeman GJ, Sharpe AH.

J Immunol. 2005 Dec 1;175(11):7372-9.


Expression of programmed-death receptor ligands 1 and 2 may contribute to the poor stimulatory potential of murine immature dendritic cells.

Chen C, Qu QX, Huang JA, Zhu YB, Ge Y, Wang Q, Zhang XG.

Immunobiology. 2007;212(3):159-65. Epub 2007 Mar 23.


Interaction of human PD-L1 and B7-1.

Butte MJ, Peña-Cruz V, Kim MJ, Freeman GJ, Sharpe AH.

Mol Immunol. 2008 Aug;45(13):3567-72. doi: 10.1016/j.molimm.2008.05.014. Epub 2008 Jun 27.


Expression of programmed death 1 ligands by murine T cells and APC.

Yamazaki T, Akiba H, Iwai H, Matsuda H, Aoki M, Tanno Y, Shin T, Tsuchiya H, Pardoll DM, Okumura K, Azuma M, Yagita H.

J Immunol. 2002 Nov 15;169(10):5538-45.


Programmed cell death 1 (PD-1) and its ligand PD-L1 are required for allograft tolerance.

Wang L, Han R, Hancock WW.

Eur J Immunol. 2007 Oct;37(10):2983-90.


B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance.

Park JJ, Omiya R, Matsumura Y, Sakoda Y, Kuramasu A, Augustine MM, Yao S, Tsushima F, Narazaki H, Anand S, Liu Y, Strome SE, Chen L, Tamada K.

Blood. 2010 Aug 26;116(8):1291-8. doi: 10.1182/blood-2010-01-265975. Epub 2010 May 14.


Striking dichotomy of PD-L1 and PD-L2 pathways in regulating alloreactive CD4(+) and CD8(+) T cells in vivo.

Habicht A, Kewalaramani R, Vu MD, Demirci G, Blazar BR, Sayegh MH, Li XC.

Am J Transplant. 2007 Dec;7(12):2683-92. Epub 2007 Oct 9.


Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.

Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, Greenfield EA, Freeman GJ.

J Immunol. 2003 Feb 1;170(3):1257-66.


The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival.

Shen L, Jin Y, Freeman GJ, Sharpe AH, Dana MR.

J Immunol. 2007 Sep 15;179(6):3672-9.


Time courses of B7 family molecules expressed on activated T-cells and their biological significance.

Sun ZW, Qiu YH, Shi YJ, Tao R, Chen J, Ge Y, Hu YM, Ma HB, Shi Q, Zhang XG.

Cell Immunol. 2005 Jul-Aug;236(1-2):146-53. Epub 2005 Sep 12.


Partial restoration of T-cell function in aged mice by in vitro blockade of the PD-1/ PD-L1 pathway.

Lages CS, Lewkowich I, Sproles A, Wills-Karp M, Chougnet C.

Aging Cell. 2010 Oct;9(5):785-98. doi: 10.1111/j.1474-9726.2010.00611.x.


RNA interference targeting programmed death receptor-1 improves immune functions of tumor-specific T cells.

Borkner L, Kaiser A, van de Kasteele W, Andreesen R, Mackensen A, Haanen JB, Schumacher TN, Blank C.

Cancer Immunol Immunother. 2010 Aug;59(8):1173-83. doi: 10.1007/s00262-010-0842-0. Epub 2010 Mar 27.


Specific and high-affinity binding of tetramerized PD-L1 extracellular domain to PD-1-expressing cells: possible application to enhance T cell function.

Terawaki S, Tanaka Y, Nagakura T, Hayashi T, Shibayama S, Muroi K, Okazaki T, Mikami B, Garboczi DN, Honjo T, Minato N.

Int Immunol. 2007 Jul;19(7):881-90. Epub 2007 Jul 2.


PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model.

Zhang L, Gajewski TF, Kline J.

Blood. 2009 Aug 20;114(8):1545-52. doi: 10.1182/blood-2009-03-206672. Epub 2009 May 5.

Supplemental Content

Support Center